TP53 and ovarian cancer: The GANNET53 trial, a small phase I/II study for platinum-resistant ovarian cancer, combined paclitaxel with Ganetespib to target mutant p53 and showed no dose-limiting toxicities, leading to its selection for a randomized phase II trial.